27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- The FDA has cleared RA Medical Systems Inc's (NYSE:RMED) DABRA 2.0 catheter as part of the DABRA Excimer Laser System.
- This next-generation DABRA catheter features enhancements, including a braided over jacket design intended to improve deliverability and kink resistance when navigating tortuous anatomy and six-month shelf life.
- "While we are pleased to receive this regulatory clearance, it comes as our Board continues its evaluation of strategic alternatives to optimize our Company's path forward in the current challenging economic environment," said Will McGuire, Ra Medical Systems CEO.
- "As we have previously announced, the DABRA 2.0 catheter represents an interim step in our work to develop a guidewire-compatible version of the DABRA catheter. At this time, we have no plans to commercialize the DABRA 2.0," he added.
- In May, RA Medical Systems disclosed that it is reviewing strategic alternatives.
- In June, the company reduced its workforce by approximately 65%.
- Price Action: RMED shares are up 52.1% at $0.47 during the premarket session on the last check Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!